Conn J.W. Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 1955, 45(1):3.
Young W.F. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf) 2007, 66(5):607-618.
Kearney P.M., Whelton M., Reynolds K., Muntner P., Whelton P.K., He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005, 365(9455):217-223.
Chao C.-T., Wu V.-C., Kuo C.-C., Lin Y.-H., Chang C.-C., Chueh S.J., et al. Diagnosis and management of primary aldosteronism: an updated review. Ann Med 2013, 45(4):375-383.
Funder J.W., Carey R.M., Fardella C., Gomez-Sanchez C.E., Mantero F., Stowasser M., et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metabol 2008, 93(9):3266-3281.
Milliez P., Girerd X., Plouin P.-F., Blacher J., Safar M.E., Mourad J.-J. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005, 45(8):1243-1248.
Stowasser M., Sharman J., Leano R., Gordon R.D., Ward G., Cowley D., et al. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrinol Metabol 2005, 90(9):5070-5076.
Mulatero P., Milan A., Williams T.A., Veglio F. Mineralocorticoid receptor blockade in the protection of target organ damage. Cardiovasc Hematol Agents Med Chem 2006, 4(1):75-91.
Sawka A.M., Young W.F., Thompson G.B., Grant C.S., Farley D.R., Leibson C., et al. Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann Intern Med 2001, 135(4):258-261.
Milsom S., Espiner E., Nicholls M., Gwynne J., Perry E. The blood pressure response to unilateral adrenalectomy in primary aldosteronism. QJM 1986, 61(3):1141-1151.
Celen O., O'Brien M.J., Melby J.C., Beazley R.M. Factors influencing outcome of surgery for primary aldosteronism. Arch Surg 1996, 131(6):646-650.
Wu V.-C., Chueh S.-C., Chang H.-W., Lin L.-Y., Liu K.-L., Lin Y.-H., et al. Association of kidney function with residual hypertension after treatment of aldosterone-producing adenoma. Am J Kidney Dis 2009, 54(4):665-673.
Lim P., Jung R., MacDonald T., et al. Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study. Br J Clin Pharmacol 1999, 48:756-760.
Ghose R.P., Hall P.M., Bravo E.L. Medical management of aldosterone-producing adenomas. Ann Intern Med 1999, 131(2):105-108.
Lim P.O., Young W.F., MacDonald T.M. A review of the medical treatment of primary aldosteronism. J Hypertens 2001, 19(3):353-361.
Brown J., Davies D., Ferriss J., Fraser R., Haywood E., Lever A., et al. Comparison of surgery and prolonged spironolactone therapy in patients with hypertension, aldosterone excess, and low plasma renin. Br Med J 1972, 2(5816):729.
Catena C., Colussi G., Nadalini E., Chiuch A., Baroselli S., Lapenna R., et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008, 168(1):80-85.
Alvarez-Madrazo S., Padmanabhan S., Mayosi B.M., Watkins H., Avery P., Wallace A.M., et al. Familial and phenotypic associations of the aldosterone renin ratio. J Clin Endocrinol Metabol 2009, 94(11):4324-4333.
Seccia T.M., Fassina A., Nussdorfer G.G., Pessina A.C., Rossi G.P. Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn's syndrome with an ominous clinical course. Endocr Relat Cancer 2005, 12(1):149-159.
Saner-Amigh K., Mayhew B.A., Mantero F., Schiavi F., White P.C., Rao C.V., et al. Elevated expression of luteinizing hormone receptor in aldosterone-producing adenomas. J Clin Endocrinol Metabol 2006, 91(3):1136-1142.
Ye P., Mariniello B., Mantero F., Shibata H., Rainey W.E. G-protein-coupled receptors in aldosterone-producing adenomas: a potential cause of hyperaldosteronism. J Endocrinol 2007, 195(1):39-48.
Ehrhart-Bornstein M., Lamounier-Zepter V., Schraven A., Langenbach J., Willenberg H., Barthel A., et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci 2003, 100(24):14211-14216.
Goodfriend T.L., Calhoun D.A. Resistant hypertension, obesity, sleep apnea, and aldosterone theory and therapy. Hypertension 2004, 43(3):518-524.
Rossi G.P., Belfiore A., Bernini G., Fabris B., Caridi G., Ferri C., et al. Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. J Clin Endocrinol Metabol 2008, 93(7):2566-2571.
Sutherland D., Ruse J., Laidlaw J. Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Can Med Assoc J 1966, 95(22):1109.
LIfton R.P., Dluhy R.G., Powers M., Rich G.M., Cook S., Ulick S., et al. A chimaeric 11 β-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992, 355:262-265.
Geller D.S., Zhang J., Wisgerhof M.V., Shackleton C., Kashgarian M., Lifton R.P. A novel form of human Mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism. J Clin Endocrinol Metabol 2008, 93(8):3117-3123.
Choi M., Scholl U.I., Yue P., Björklund P., Zhao B., Nelson-Williams C., et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 2011, 331(6018):768-772.
Funder J.W. The genetic basis of primary aldosteronism. Curr Hypertens Rep 2012, 14(2):120-124.
Williams T.A., Monticone S., Veglio F., Mulatero P. Familial hyperaldosteronism type III. Primary aldosteronism 2014, 99-108. Springer.
Stowasser M., Gordon R.D. Familial hyperaldosteronism type II. Primary aldosteronism 2014, 87-97. Springer.
Gordon R. Mineralocorticoid hypertension. Lancet 1994, 344(8917):240-243.
Mattsson C., Young W.F. Primary aldosteronism: diagnostic and treatment strategies. Nat Clin Pract Nephrol 2006, 2(4):198-208.
Labinson P.T., White W.B., Tendler B.E., Mansoor G.A. Primary hyperaldosteronism associated with hypertensive emergencies. Am J Hypertens 2006, 19(6):623-627.
Mulatero P., Stowasser M., Loh K.-C., Fardella C.E., Gordon R.D., Mosso L., et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metabol 2004, 89(3):1045-1050.
Rossi G.P., Bernini G., Caliumi C., Desideri G., Fabris B., Ferri C., et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006, 48(11):2293-2300.
Bernini G., Galetta F., Franzoni F., Bardini M., Taurino C., Bernardini M., et al. Arterial stiffness, intima-media thickness and carotid artery fibrosis in patients with primary aldosteronism. J Hypertens 2008, 26(12):2399-2405.
Rossi G.P., Bernini G., Desideri G., Fabris B., Ferri C., Giacchetti G., et al. Renal damage in primary aldosteronism results of the PAPY study. Hypertension 2006, 48(2):232-238.
Sechi L.A., Novello M., Lapenna R., Baroselli S., Nadalini E., Colussi G.L., et al. Long-term renal outcomes in patients with primary aldosteronism. JAMA 2006, 295(22):2638-2645.
Chhokar V.S., Sun Y., Bhattacharya S.K., Ahokas R.A., Myers L.K., Xing Z., et al. Hyperparathyroidism and the calcium paradox of aldosteronism. Circulation 2005, 111(7):871-878.
Chau K., Holmes D., Melck A., Chan-Yan C. Secondary hypertension due to concomitant aldosterone-producing adenoma and parathyroid adenoma. Am J Hypertens 2015, 28(2):280-282.
Reincke M., Meisinger C., Holle R., Quinkler M., Hahner S., Beuschlein F., et al. Is primary aldosteronism associated with diabetes mellitus? Results of the German Conn's registry. Horm Metab Res 2010, 42(6):435.
Matrozova J., Steichen O., Amar L., Zacharieva S., Jeunemaitre X., Plouin P.-F. Fasting plasma glucose and serum lipids in patients with primary aldosteronism a controlled cross-sectional study. Hypertension 2009, 53(4):605-610.
Gordon R.D., Stowasser M., Rutherford J.C. Primary aldosteronism: are we diagnosing and operating on too few patients?. World J Surg 2001, 25(7):941-947.
Stowasser M., Gordon R.D., Gunasekera T.G., Cowley D.C., Ward G., Archibald C., et al. High rate of detection of primary aldosteronism, including surgically treatable forms, after non-selective screening of hypertensive patients. J Hypertens 2003, 21(11):2149-2157.
Gordon R.D. The challenge of more robust and reproducible methodology in screening for primary aldosteronism. J Hypertens 2004, 22(2):251-255.
Montori V.M., Young W.F. Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism: a systematic review of the literature. Endocrinol Metab Clin North Am 2002, 31(3):619-632.
Tiu S.-C., Choi C.-H., Shek C.-C., Ng Y.-W., Chan F.K., Ng C.-M., et al. The use of aldosterone-renin ratio as a diagnostic test for primary hyperaldosteronism and its test characteristics under different conditions of blood sampling. J Clin Endocrinol Metabol 2005, 90(1):72-78.
McKenna T.J., Sequeira S.J., Heffernan A., Joseph C., Cunningham S. Diagnosis under random conditions of all disorders of the renin-angiotensin-aldosterone axis, including primary hyperaldosteronism. J Clin Endocrinol Metabol 1991, 73(5):952-957.
Gomez-Sanchez C.E., Holland B. Urinary tetrahydroaldosterone and aldosterone-18-glucuronide excretion in white and black normal subjects and hypertensive patients*. J Clin Endocrinol Metabol 1981, 52(2):214-219.
Mayes D., Furuyama S., Kem D., Nugent C. A radioimmunoassay for plasma aldosterone 1. J Clin Endocrinol Metabol 1970, 30(5):682-685.
Jones J.C., Carter G.D., Macgregor G.A. Interference by polar metabolites in a direct radioimmunoassay for plasma aldosterone. Ann Clin Biochem 1981, 18(1):54-59.
Stabler T., Siegel A. Chemiluminescence immunoassay of aldosterone in serum. Clin Chem 1991, 37(11):1987-1989.
Perschel F.H., Schemer R., Seiler L., Reincke M., Deinum J., Maser-Gluth C., et al. Rapid screening test for primary hyperaldosteronism: ratio of plasma aldosterone to renin concentration determined by fully automated chemiluminescence immunoassays. Clin Chem 2004, 50(9):1650-1655.
Iervasi A., Zucchelli G., Turchi S., Emdin M., Passino C., Ripoli A., et al. Analytical and clinical performance of an automated chemiluminescent immunoassay for direct renin measurement: comparison with PRA and aldosterone assays. Immuno-anal Biol Spec 2005, 20(4):257-262.
Schirpenbach C., Seiler L., Maser-Gluth C., Beuschlein F., Reincke M., Bidlingmaier M. Automated chemiluminescence-immunoassay for aldosterone during dynamic testing: comparison to radioimmunoassays with and without extraction steps. Clin Chem 2006, 52(9):1749-1755.
Pizzolo F., Corgnati A., Guarini P., Pavan C., Bassi A., Corrocher R., et al. Plasma aldosterone assays: comparison between chemiluminescence-based and RIA methods. Clin Chem 2006, 52(7):1431a-1432a.
Van Der Gugten J.G., Dubland J., Liu H.-F., Wang A., Joseph C., Holmes D.T. Determination of serum aldosterone by liquid chromatography and tandem mass spectrometry: a liquid-liquid extraction method for the ABSCIEX API-5000 mass spectrometry system. J Clin Pathol 2012, 65(5):457-462.
Holmes D.T. cp-R, an interface the R programming language for clinical laboratory method comparisons. Clin Biochem 2015, 48(3):192-195.
Taylor P.J., Cooper D.P., Gordon R.D., Stowasser M. Measurement of aldosterone in human plasma by semiautomated HPLC-tandem mass spectrometry. Clin Chem 2009, 55(6):1155-1162.
Hinchliffe E., Carter S., Owen L.J., Keevil B.G. Quantitation of aldosterone in human plasma by ultra high performance liquid chromatography tandem mass spectrometry. J Chromatogr B 2013, 913:19-23.
Guo T., Taylor R.L., Singh R.J., Soldin S.J. Simultaneous determination of 12 steroids by isotope dilution liquid chromatography-photospray ionization tandem mass spectrometry. Clin Chim Acta 2006, 372(1):76-82.
Ray J.A., Kushnir M.M., Palmer J., Sadjadi S., Rockwood A.L., Meikle A.W. Enhancement of specificity of aldosterone measurement in human serum and plasma using 2D-LC-MS/MS and comparison with commercial immunoassays. J Chromatogr B 2014, 970:102-107.
Turpeinen U., Hämäläinen E., Stenman U.-H. Determination of aldosterone in serum by liquid chromatography-tandem mass spectrometry. J Chromatogr B 2008, 862(1):113-118.
Van Der Gugten J.G., Crawford M., Grant R.P., Holmes D.T. Supported liquid extraction offers improved sample preparation for aldosterone analysis by liquid chromatography tandem mass spectrometry. J Clin Pathol 2012, 65(11):1045-1048.
Owen L.J., Keevil B.G. Supported liquid extraction as an alternative to solid phase extraction for LC-MS/MS aldosterone analysis?. Ann Clin Biochem 2013, 50(Pt 5):489-491.
French D. Development and validation of a serum total testosterone liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay calibrated to NIST SRM 971. Clin Chim Acta 2013, 415:109-117.
Referenzinstitut für bioanalytik [accessed: 2014-11-20]. http://www.dgkl-rfb.de.
Danser A.J., Batenburg W.W., van Esch J.H. Prorenin and the (pro)renin receptor-an update. Nephrol Dial Transplant 2007, 22(5):1288-1292.
Campbell D.J., Nussberger J., Stowasser M., Danser A.J., Morganti A., Frandsen E., et al. Activity assays and immunoassays for plasma renin and prorenin: information provided and precautions necessary for accurate measurement. Clin Chem 2009, 55(5):867-877.
Pitarresi T.M., Rubattu S., Heinrikson R., Sealey J. Reversible cryoactivation of recombinant human prorenin. J Biol Chem 1992, 267(17):11753-11759.
Nussberger J., Gasparo M.D., Juillerat L., Guyenne T., Mooser V., Waeber B., et al. Rapid measurement of total and active renin: plasma concentrations during acute and sustained converting enzyme inhibition with CGS 14824A. Clin Exp Hypertens 1987, 9(8-9):1353-1366.
Sealey J.E., Gordon R.D., Mantero F. Plasma renin and aldosterone measurements in low renin hypertensive states. Trends Endocrinol Metab 2005, 16(3):86-91.
Campbell D.J., Kladis A., Skinner S.L., Whitworth J.A. Characterization of angiotensin peptides in plasma of anephric man. J Hypertens 1991, 9(3):265-266.
Cawood M.L. Measurement of plasma renin activity. Hormone assays in biological fluids 2006, 187-196. Springer.
Sealey J.E., Laragh J.H. Radioimmunoassay of plasma renin activity. Seminars in nuclear medicine 1975, vol. 5:189-202. Elsevier.
Barrett J.D., Eggena P., Sambhi M.P. Influence of angiotensinase inhibitors on the enzymatic activity of renin. Biochem Med 1976, 16(2):157-168.
Carter S., Owen L., Kerstens M., Dullaart R., Keevil B. A liquid chromatography tandem mass spectrometry assay for plasma renin activity using online solid-phase extraction. Ann Clin Biochem 2012, 49(6):570-579.
Poulsen K., Jørgensen J. An easy radioimmunological microassay of renin activity, concentration and substrate in human and animal plasma and tissues based on angiotensin I trapping by antibody. J Clin Endocrinol Metabol 1974, 39(5):816-825.
Bystrom C.E., Salameh W., Reitz R., Clarke N.J. Plasma renin activity by LC-MS/MS: development of a prototypical clinical assay reveals a subpopulation of human plasma samples with substantial peptidase activity. Clin Chem 2010, 56(10):1561-1569.
Sealey J.E., Laragh J.H. Plasma renin activity enzyme-kinetic assay: protection of angiotensin i from bacterial degradation. Clin Chem 2011, 57(3):529-530.
Fredline V.F., Kovacs E.M., Taylor P.J., Johnson A.G. Measurement of plasma renin activity with use of HPLC-electrospray-tandem mass spectrometry. Clin Chem 1999, 45(5):659-664.
Owen L.J., Adaway J., Morris K., Lockhart S., Keevil B.G. A widely applicable plasma renin activity assay by LC-MS/MS with offline solid phase extraction. Ann Clin Biochem 2014, 51(Pt 3):409-411.
Camenzind A.G., van der Gugten J.G., Popp R., Holmes D.T., Borchers C.H. Development and evaluation of an immuno-MALDI (iMALDI) assay for angiotensin i and the diagnosis of secondary hypertension. Clin Proteomics 2013, 10:20.
Popp R., Malmström D., Chambers A.G., Lin D., Camenzind A.G., van der Gugten J.G., Holmes D.T., Pugia M., Jaremek M., Cornett S. et al. An automated assay for the clinical measurement of plasma renin activity by immuno-MALDI (iMALDI). Biochim Biophys Acta Protein Proteomics 2015, [in press]. 10.1016/j.bbapap.2014.10.008.
Sealey J.E., Laragh J.H. Searching out low renin patients: limitations of some commonly used methods. Am J Med 1973, 55(3):303-314.
Non WHO reference material 86/536 angiotensin I [accessed: 2014-11-20]. http://www.nibsc.org/documents/ifu/86-536.pdf.
Stowasser M. Update in primary aldosteronism. J Clin Endocrinol Metab 2015, 100(1):1-10.
Deinum J., Derkx F.H., Schalekamp M.A. Improved immunoradiometric assay for plasma renin. Clin Chem 1999, 45(6):847-854.
Hartman D., Sagnella G.A., Chesters C.A., MacGregor G.A. Direct renin assay and plasma renin activity assay compared. Clin Chem 2004, 50(11):2159-2161.
Juutilainen A., Savolainen K., Romppanen J., Turpeinen U., Hämäläinen E., Kemppainen J., et al. Combination of LC-MS/MS aldosterone and automated direct renin in screening for primary aldosteronism. Clin Chim Acta 2014, 433:209-215.
Dorrian C., Toole B., Alvarez-Madrazo S., Kelly A., Connell J., Wallace A. A screening procedure for primary aldosteronism based on the diasorin liaison automated chemiluminescent immunoassay for direct renin. Ann Clin Biochem 2010, 47(3):195-199.
Lonati C., Bassani N., Gritti A., Biganzoli E., Morganti A. Measurement of plasma renin concentration instead of plasma renin activity decreases the positive aldosterone-to-renin ratio tests in treated patients with essential hypertension. J Hypertens 2014, 32(3):627-634.
Ahmed A.H., Gordon R.D., Taylor P.J., Ward G., Pimenta E., Stowasser M. Are women more at risk of false-positive primary aldosteronism screening and unnecessary suppression testing than men?. J Clin Endocrinol Metabol 2010, 96(2):E340-E346.
Ahmed A.H., Gordon R.D., Taylor P.J., Ward G., Pimenta E., Stowasser M. Effect of contraceptives on aldosterone/renin ratio may vary according to the components of contraceptive, renin assay method, and possibly route of administration. J Clin Endocrinol Metabol 2011, 96(6):1797-1804.
Stowasser M., Gordon R.D. The aldosterone-renin ratio: role and problems. Primary aldosteronism 2014, 109-126. Springer.
Rossi G.P., Barisa M., Belfiore A., Desideri G., Ferri C., Letizia C., et al. The aldosterone-renin ratio based on the plasma renin activity and the direct renin assay for diagnosing aldosterone-producing adenoma. J Hypertens 2010, 28(9):1892-1899.
Manolopoulou J., Bennett A., Grimminger P., Fischer E., Pallauf A., Diederich S., Reincke M., Bidlingmaier M. Sat-226: ratio of plasma aldosterone to plasma renin (ARR) using two fully automated chemiluminescence immunoassays. Endocrine Society Annual Meeting 2012.
Locsei Z., Racz K., Patocs A., Kovacs G.L., Toldy E. Influence of sampling and storage conditions on plasma renin activity and plasma renin concentration. Clin Chim Acta 2009, 402(1):203-205.
French D., Terrazas E. The successful implementation of a licensed data management interface between a Sunquest(®) laboratory information system and an AB SCIEX™ mass spectrometer. J Pathol Inform 2013, 4(1).
Montori V.M., Schwartz G.L., Chapman A.B., Boerwinkle E., Turner S.T. Validity of the aldosterone-renin ratio used to screen for primary aldosteronism. Mayo Clinic Proceedings 2001, vol. 76:877-882. Elsevier.
Schwartz G.L., Chapman A.B., Boerwinkle E., Kisabeth R.M., Turner S.T. Screening for primary aldosteronism: implications of an increased plasma aldosterone/renin ratio. Clin Chem 2002, 48(11):1919-1923.
Young W.F. Primary aldosteronism: update on diagnosis and treatment. Endocrinologist 1997, 7(4):213-221.
Loh K.-C., Koay E.S., Khaw M.-C., Emmanuel S.C., Young W.F. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metabol 2000, 85(8):2854-2859.
Mosso L., Carvajal C., González A., Barraza A., Avila F., Montero J., et al. Primary aldosteronism and hypertensive disease. Hypertension 2003, 42(2):161-165.
Stowasser M., Gordon R.D. Primary aldosteronism-careful investigation is essential and rewarding. Mol Cell Endocrinol 2004, 217(1):33-39.
Sustarsic R.K., Manolopoulou J., Grimminger P., Roffe C.M., Reincke M., Bidlingmaier M. Sat-0850: Primary aldosteronism: biochemical workup from screening to AVS to post-op control on a single automated platform. Endocrine Society Annual Meeting 2014.
Ahmed A.H., Calvird M., Gordon R.D., Taylor P.J., Ward G., Pimenta E., et al. Effects of two selective serotonin reuptake inhibitor antidepressants, sertraline and escitalopram, on aldosterone/renin ratio in normotensive depressed male patients. J Clin Endocrinol Metabol 2011, 96(4):1039-1045.
Gordon R., Tunny T. Aldosterone-producing-adenoma (APA): effect of pregnancy. Clin Exp Hypertens 1982, 4(9-10):1685-1693.
Sharma S.K., Evans D.B., Hui J.O., Heinrikson R.L. Could angiotensin i be produced from a renin substrate by the HIV-1 protease?. Anal Biochem 1991, 198(2):363-367.
Mulatero P., Dluhy R.G., Giacchetti G., Boscaro M., Veglio F., Stewart P.M. Diagnosis of primary aldosteronism: from screening to subtype differentiation. Trends Endocrinol Metab 2005, 16(3):114-119.
Mulatero P., Monticone S., Bertello C., Mengozzi G., Tizzani D., Iannaccone A., et al. Confirmatory tests in the diagnosis of primary aldosteronism. Horm Metab Res 2010, 42(06):406-410.
Haase M., Gruber M., Gao X., Vonend O., Willenberg H.S. Confirmatory testing for primary aldosteronism. Primary aldosteronism 2014, 127-140. Springer.
Mulatero P., Milan A., Fallo F., Regolisti G., Pizzolo F., Fardella C., et al. Comparison of confirmatory tests for the diagnosis of primary aldosteronism. J Clin Endocrinol Metabol 2006, 91(7):2618-2623.
Giacchetti G., Ronconi V., Lucarelli G., Boscaro M., Mantero F. Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for a standardized protocol. J Hypertens 2006, 24(4):737-745.
Wwinberger M.H., Grim C.E., Hollifield J.W., Kem D.C., Ganguly A., Kramer N.J., et al. Primary aldosteronism diagnosis, localization, and treatment. Ann Intern Med 1979, 90(3):386-391.
Ahmed A.H., Cowley D., Wolley M., Gordon R.D., Xu S., Taylor P.J., Stowasser M. Seated saline suppression testing for the diagnosis of primary aldosteronism-a preliminary study. J Clin Endocrinol Metab 2014, 99(8):2745-2753.
Daunt N. Adrenal vein sampling: how to make it quick, easy, and successful. Radiographics 2005, 25(Suppl. 1):S143-S158.
Young W.F., Stanson A.W. What are the keys to successful adrenal venous sampling (AVS) in patients with primary aldosteronism?. Clin Endocrinol (Oxf) 2009, 70(1):14-17.
Van Der Gugten G., Holmes D.T. An LC-MS/MS method for the measurement of aldosterone, cortisol, 11-deoxycorticosterone, corticosterone, 18-hydroxycorticosterone and 18-hydroxy-11-deoxycorticosterone with application to adrenal vein sampling. Clin Chem 2012, 58(S10):A80-A81.
Peitzsch M., Dekkers T., Haase M., Sweep F.C., Quack I., Antoch G., Siegert G., Lenders J.W., Deinum J., Willenberg H.S., et al. An LC-MS/MSmethod for steroid profiling during adrenal venous sampling for investigation of primary aldosteronism. J Steroid Biochem Mol Biol 2015, 145:75-84.
Clark Z. 3 strategies to stop a pervasive high-throughput sample preparation quality problem you likely didn't know you had [Online; accessed 15-December-2014]. https://www.msacl.org/documents/MSACL_2014_US_eProgram.pdf.
Solar M., Ceral J., Krajina A., Ballon M., Malirova E., Brodak M., et al. Adrenal venous sampling: where is the aldosterone disappearing to?. Cardiovasc Intervent Radiol 2010, 33(4):760-765.
Kempers M.J., Lenders J.W., van Outheusden L., van der Wilt G.J., Kool L.J.S., Hermus A.R., et al. Systematic review: diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism. Ann Intern Med 2009, 151(5):329-337.
Rossi G.P., Auchus R.J., Brown M., Lenders J.W., Naruse M., Plouin P.F., et al. An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism. Hypertension 2014, 63(1):151-160.
Young W.F., Stanson A.W., Thompson G.B., Grant C.S., Farley D.R., van Heerden J.A. Role for adrenal venous sampling in primary aldosteronism. Surgery 2004, 136(6):1227-1235.
Vonend O., Ockenfels N., Gao X., Allolio B., Lang K., Mai K., et al. Adrenal venous sampling evaluation of the German Conn's registry. Hypertension 2011, 57(5):990-995.
Elliott P., Holmes D.T. Adrenal vein sampling: substantial need for technical improvement at regional referral centres. Clin Biochem 2013, 46(15):1399-1404.
Young W.F., Stanson A.W., Grant C.S., Thompson G.B., van Heerden J.A. Primary aldosteronism: adrenal venous sampling. Surgery 1996, 120(6):913-920.
Harvey A., Kline G., Pasieka J.L. Adrenal venous sampling in primary hyperaldosteronism: comparison of radiographic with biochemical success and the clinical decision-making with "less than ideal" testing. Surgery 2006, 140(6):847-855.
Rossi G.P., Pitter G., Bernante P., Motta R., Feltrin G., Miotto D. Adrenal vein sampling for primary aldosteronism: the assessment of selectivity and lateralization of aldosterone excess baseline and after adrenocorticotropic hormone (ACTH) stimulation. J Hypertens 2008, 26(5):989-997.
Seccia T.M., Miotto D., De Toni R., Pitter G., Mantero F., Pessina A.C., et al. Adrenocorticotropic hormone stimulation during adrenal vein sampling for identifying surgically curable subtypes of primary aldosteronism comparison of 3 different protocols. Hypertension 2009, 53(5):761-766.
Omura M., Sasano H., Saito J., Yamaguchi K., Kakuta Y., Nishikawa T. Clinical characteristics of aldosterone-producing microadenoma, macroadenoma, and idiopathic hyperaldosteronism in 93 patients with primary aldosteronism. Hypertens Res 2006, 29(11):883-889.
Satoh F., Abe T., Tanemoto M., Nakamura M., Abe M., Uruno A., et al. Localization of aldosterone-producing adrenocortical adenomas: significance of adrenal venous sampling. Hypertens Res 2007, 30(11):1083-1095.
Mengozzi G., Rossato D., Bertello C., Garrone C., Milan A., Pagni R., et al. Rapid cortisol assay during adrenal vein sampling in patients with primary aldosteronism. Clin Chem 2007, 53(11):1968-1971.
Auchus R.J., Michaelis C., Wians F.H., Dolmatch B.L., Josephs S.C., Trimmer C.K., et al. Rapid cortisol assays improve the success rate of adrenal vein sampling for primary aldosteronism. Ann Surg 2009, 249(2):318-321.
Betz M.J., Degenhart C., Fischer E., Pallauf A., Brand V., Linsenmaier U., et al. Adrenal vein sampling using rapid cortisol assays in primary aldosteronism is useful in centers with low success rates. Eur J Endocrinol 2011, 165(2):301-306.
Baba Y., Hayashi S., Nakajo M. Are catecholamine-derived indexes in adrenal venous sampling useful for judging selectivity and laterality in patients with primary aldosteronism?. Endocrine 2013, 43(3):611-617.
Young W.F., Du Plessis H., Thompson G.B., Grant C.S., Farley D.R., Richards M.L., et al. The clinical conundrum of corticotropin-independent autonomous cortisol secretion in patients with bilateral adrenal masses. World J Surg 2008, 32(5):856-862.
